{
  "study_id": "NCT01492101",
  "study_title": "Etirinotecan pegol (NKTR-102) versus treatment of physician's choice in women with advanced breast cancer previously treated with an anthracycline, a taxane, and capecitabine (BEACON): a randomised, open-label, multicentre, phase 3 trial",
  "table_name": "Patient Demographics",
  "table_title": "Patient Demographics (Intention-to-Treat Population)",
  "description": "No table of baseline patient demographics was found in the provided document. The number of patients in each group was extracted from the text in the 'Findings' section.",
  "footnotes": [],
  "groups": [
    {
      "name": "Etirinotecan pegol",
      "n": 429,
      "type": "Intervention"
    },
    {
      "name": "Treatment of physician's choice",
      "n": 423,
      "type": "Control"
    }
  ],
  "characteristics": [
    {
      "original_label": "Number of patients",
      "standardized_name": "Participant count",
      "category": "Sample size",
      "time_point": "Baseline",
      "is_sub_characteristic": false,
      "group_data": [
        {
          "group_name": "Etirinotecan pegol",
          "data_type": "numeric_single",
          "value": 429.0,
          "raw_string": "429",
          "n_for_value": 429
        },
        {
          "group_name": "Treatment of physician's choice",
          "data_type": "numeric_single",
          "value": 423.0,
          "raw_string": "423",
          "n_for_value": 423
        }
      ]
    }
  ]
}